LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

Article2024

1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, G.V. Long, V.G. Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Muhammad A. Khattak, M.S. Carlino, Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, P. Lorigan, D. Grebennik, C. Krepler, Sandrine Marréaud, Stefan Suciu, C. Robert

Article2022

804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

Alexander M.M. Eggermont, Michal Kiciński, C.U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, A. Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, S.S. Puig Sarda, P.A. Ascierto, Paul Lorigan, Dmitri Grebennik, Nageatte Ibrahim, Sandrine Marréaud, Stefan Suciu, Caroline Robert

Article2019

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

Jason J. Luke, Paolo A. Ascierto, Matteo S. Carlino, Jeffrey E. Gershenwald, Jean-Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Caroline Robert, Merrick I. Ross, Richard A Scolyer, Charles H. Yoon, Andrew Poklepovic, Piotr Rutkowski, James R. Anderson, Sama Ahsan, Nageatte Ibrahim, Alexander M.M. Eggermont

Article2019

Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.

Jason J. Luke, Paolo A. Ascierto, Matteo S. Carlino, Alexander Eggermont, Jean‐Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Caroline Robert, Jeffrey E. Gershenwald, Andrew Poklepovic, Merrick I. Ross, Richard A Scolyer, Charles H. Yoon, James R. Anderson, Sama Ahsan, Nageatte Ibrahim, Vernon K. Sondak

Article2018

Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma

Adnan Khattak, Caroline Robert, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Paul Lorigan, Nageatte Ibrahim, Stefan Suciu, A. M. M. Eggermont

Discussion(0)

Related publications